Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma.
Th2 T cell immune-driven inflammation plays an important role in allergic asthma. We studied the effect of counterbalancing Th1 T cells in an asthma model in Brown Norway rats that favors Th2 responses. Rats received i.v. transfers of syngeneic allergen-specific Th1 or Th2 cells, 24 h before aerosol exposure to allergen, and were studied 18-24 h later. Adoptive transfer of OVA-specific Th2 cells, but not Th1 cells, and OVA, but not BSA exposure, induced bronchial hyperresponsiveness (BHR) to acetylcholine and eosinophilia in a cell number-dependent manner. Importantly, cotransfer of OVA-specific Th1 cells dose-dependently reversed BHR and bronchoalveolar lavage (BAL) eosinophilia, but not mucosal eosinophilia. OVA-specific Th1 cells transferred alone induced mucosal eosinophilia, but neither BHR nor BAL eosinophilia. Th1 suppression of BHR and BAL eosinophilia was allergen specific, since cotransfer of BSA-specific Th1 cells with the OVA-specific Th2 cells was not inhibitory when OVA aerosol alone was used, but was suppressive with OVA and BSA challenge. Furthermore, recipients of Th1 cells alone had increased gene expression for IFN-gamma in the lungs, while those receiving Th2 cells alone showed increased IL-4 mRNA. Importantly, induction of these Th2 cytokines was inhibited in recipients of combined Th1 and Th2 cells. Anti-IFN-gamma treatment attenuated the down-regulatory effect of Th1 cells. Allergen-specific Th1 cells down-regulate efferent Th2 cytokine-dependent BHR and BAL eosinophilia in an asthma model via mechanisms that depend on IFN-gamma. Therapy designed to control the efferent phase of established asthma by augmenting down-regulatory Th1 counterbalancing mechanisms should be effective.
Huang
T J
TJ
Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom.
MacAry
P A
PA
Eynott
P
P
Moussavi
A
A
Daniel
K C
KC
Askenase
P W
PW
Kemeny
D M
DM
Chung
K F
KF
D000280:Administration, Inhalation; D019264:Adoptive Transfer; D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D016535:Bronchial Hyperreactivity / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D002460:Cell Line; D018984:Epitopes, T-Lymphocyte / Q000008:administration & dosage / Q000276:immunology*; D007249:Inflammation / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D007275:Injections, Intravenous; D007371:Interferon-gamma / Q000276:immunology / Q000502:physiology*; D015847:Interleukin-4 / Q000037:antagonists & inhibitors / Q000235:genetics; D008168:Lung / Q000166:cytology / Q000276:immunology; D008297:Male; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology; D011657:Pulmonary Eosinophilia / Q000276:immunology / Q000473:pathology* / Q000517:prevention & control*; D012333:RNA, Messenger / Q000037:antagonists & inhibitors; D051381:Rats; D011914:Rats, Inbred BN; D018417:Th1 Cells / Q000276:immunology* / Q000637:transplantation; D018418:Th2 Cells / Q000276:immunology* / Q000637:transplantation
D000485:Allergens; D000911:Antibodies, Monoclonal; D018984:Epitopes, T-Lymphocyte; D012333:RNA, Messenger; D015847:Interleukin-4; D007371:Interferon-gamma; D010047:Ovalbumin